Dabrafenib plus trametinib in an elderly patient with BRAF V600E-mutant advanced pancreatic adenocarcinoma: A case report
Despite the success of anti-BRAF therapy in melanoma, data from randomized clinical trials are lacking for targeted therapy against BRAF mutations—typically the V600E variant—in pancreatic adenocarcinoma, which is associated with a poor prognosis under traditional cytotoxic chemotherapy. Here, we re...
Guardado en:
| Autores principales: | , , , , , |
|---|---|
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
Frontiers Media S.A.
2025-11-01
|
| Colección: | Frontiers in Oncology |
| Materias: | |
| Acceso en línea: | https://www.frontiersin.org/articles/10.3389/fonc.2025.1687796/full |
| Etiquetas: |
Sin Etiquetas, Sea el primero en etiquetar este registro!
|